Overview

Ixazomib for Desensitization

Status:
Completed

Trial end date:
2021-04-16

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to find out how well ixazomib (the study drug) works to desensitize highly sensitized kidney transplant recipients.

Phase:

Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Millennium Pharmaceuticals, Inc.

Treatments:

Glycine
Ixazomib